Related Experiment Videos
[Anti-aggregants in 1990]
1Centre de Thrombose et de Maladies Vasculaires, Université de Leuven, Leuven.
Insights
Antiplatelet drugs, particularly aspirin, are vital for preventing arterial thrombosis in various cardiovascular conditions. They are recommended for primary prevention in high-risk individuals and significantly reduce risks in unstable angina and myocardial infarction.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Thrombosis Prevention
Context:
- Arterial thrombosis poses a significant health risk, necessitating effective preventative strategies.
- Antiplatelet drug therapy is increasingly employed for managing and preventing thrombotic events.
- Established guidelines exist for antiplatelet use in specific cardiovascular conditions.
Purpose:
- To review the efficacy of antiplatelet drugs in preventing arterial thrombosis.
- To delineate the appropriate use of aspirin and other antiplatelet agents in various clinical scenarios.
- To assess the role of antiplatelets in primary and secondary prevention of cardiovascular events.
Summary:
- Aspirin (acetylsalicylic acid) is recommended for primary prevention of myocardial infarction in moderate-to-high risk individuals.
- Antiplatelets are effective in unstable angina, acute myocardial infarction, and secondary prevention, reducing mortality and reinfarction rates.
- Specific agents like aspirin, dipyridamole, and ticlopidine show utility in aorto-coronary grafts, coronary angioplasty, and extracorporeal circulation.
Impact:
- Demonstrates the critical role of antiplatelet therapy in reducing morbidity and mortality from arterial thrombosis.
- Provides evidence-based recommendations for optimizing antiplatelet drug selection and dosage in clinical practice.
- Highlights the benefits of aspirin and combination therapies in preventing recurrent cardiovascular and cerebrovascular events.
Abstract:
Antiplatelet drugs are increasingly used in the prevention of arterial thrombosis. Aspirin in doses of circa 300 mg day may be recommended for the primary prevention of myocardial infarction, but only in subjects at moderate to high risk of cardiovascular disease. Antiplatelet agents are useless in stable angina, but aspirin reduced by about 50% the risk of myocardial infarction and the overall mortality rate among patients with unstable angina. A lower dose of aspirin (150 mg/day) also reduces mortality by 23% in the acute phase of myocardial infarction. In doses of 300 mg/day, aspirin is useful in the secondary prevention of myocardial infarction and reduces the overall mortality rate by 15%. Various antiplatelet agents, including aspirin (alone or combined with dipyridamole) and ticlopidine, have proved useful to avoid thrombosis in aorto-coronary grafts, provided treatment begins at the latest 6 hours after surgery. The usefulness of antiplatelets has been well established in the prevention of immediate reocclusion following coronary angioplasty, but not in the prevention of late reocclusion. Aspirin and ticlopidine are useful in the extracorporeal circulation techniques. In patients with cardiac valve prosthesis, antivitamin K anticoagulants are still indispensable, but their antithrombotic effect can be reinforced by dipyridamole or aspirin. Diuretics probably provide the best primary protection against cerebrovascular accidents, although medium doses of aspirin may be considered in elderly people at high risk of such accidents. Aspirin (alone or combined with dipyridamole) and ticlopidine may be recommended for the secondary prevention of cerebral ischaemic accidents.(ABSTRACT TRUNCATED AT 250 WORDS)